false
0001533040
0001533040
2025-07-25
2025-07-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or
15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): July 25,
2025
PHIO
PHARMACEUTICALS CORP.
(Exact name of registrant as specified in its
charter)
| Delaware |
|
001-36304 |
|
45-3215903 |
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
411
Swedeland Road, Suite 23-1080
|
|
| King of
Prussia, PA |
19406 |
| (Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including
area code: (508) 767-3861
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class: |
|
Trading
Symbol(s): |
|
Name
of each exchange on which registered: |
| Common
Stock, par value $0.0001 per share |
|
PHIO |
|
The Nasdaq Capital
Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On July 25, 2025, Phio Pharmaceuticals Corp. (“Phio”)
issued press releases announcing (i) that it has entered into a comprehensive drug substance development services agreement with a U.S.
manufacturing source for drug substance and (ii) pathology results for four of five patients in the fourth cohort in Phio’s ongoing
Phase 1b dose escalation clinical trial (NCT 06014086) designed to evaluate the safety and tolerability of neoadjuvant use of INTASYL
PH-762.
The full text of the press releases are attached
hereto as Exhibits 99.1 and 99.2 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Number |
|
Description |
| 99.1 |
|
Press Release, dated July 25, 2025 |
| 99.2 |
|
Press Release, dated July 25, 2025 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 25, 2025 |
PHIO PHARMACEUTICALS CORP. |
| |
|
| |
|
|
| |
By: |
/s/
Robert J. Bitterman |
| |
Name:
Title: |
Robert J. Bitterman
President & Chief Executive Officer |
